Plasma ctDNA clinical trials

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

This study looks at lung cancer patients with specific gene changes (EGFR mutations) who have had surgery. Researchers want to understand why some cancers return after a targeted treatment called osimertinib and how to find the best future treatments if needed.